OpenAI Boosts AI Drug Discovery with Acquisition of Orchestra Bio, Merging with Rosalind Platform
OpenAI has acquired Orchestra Bio, a biopharma R&D collaboration platform, and will integrate it deeply with its own life sciences AI platform, Rosalind. This move accelerates OpenAI's strategic expansion into AI-driven drug discovery, aiming to transform traditional pharmaceutical R&D processes with generative AI.
Read More